



Nippon India Mutual Fund

Wealth sets you Free

NIMF/5/05/2023

May 3, 2023

Bombay Stock Exchange Limited
Corporate Service Department
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Sir / Madam,

Sub: Disclosure pursuant to SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

This is to inform you, that we have purchased shares of “Tatva Chintan Pharma Chem Limited” (on behalf of Nippon India Mutual Fund)

The requisite disclosure in terms of Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 is attached herewith.

Kindly acknowledge the receipt hereof.

Yours truly,

For Nippon Life India Asset Management Limited

Authorised Signatory



CC

The Company Secretary,
M/s Tatva Chintan Pharma Chem Limited,
Plot No. 502 / 17, GIDC Estate,
Ankleshwar, Bharuch,
Gujarat - 393002
Phone: 7573046951
Email: cs@tatvachintan.com; chintan@tatvachintan.com

KINCENTRIC
Best Employer

2016 | 2018 | 2019 | 2021



Nippon Life India Asset Management Limited

4th Floor, Tower A, Peninsula Business Park, Ganapatroo Kadam Marg,

Lower Parel (W), Mumbai - 400013 | CIN: L65910MH1995PLC220793

Tel: 022 6808 7000 | Fax: 022 6808 7097 | <https://mf.nipponindiaim.com>

Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A- Details of the Acquisition

1. Name of the Target Company (TC)	TATVA CHINTAN PHARMA CHEM LIMITED		
2. Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Nippon Life India Trustee Limited A/c through various schemes of Nippon India Mutual Fund Contact Address: Nippon India Mutual Fund 4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W), Mumbai - 400 013. Tel No. +91 22 6808 7000 Fax No. +91 22 6808 7097		
3. Whether the acquirer belongs to Promoter/Promoter group	No		
4. Name(s) of the Stock Exchange(s) where the shares of TC are Listed	The National Stock Exchange of India Ltd BSE Limited		
5. Details of the acquisition as follows	Number	% w. r. t. total share/ voting capital wherever applicable (*)	% w. r. t. total diluted share/ voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	10,72,492	4.8387	4.8387
b) Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others)	-	-	-
c) Voting rights (VR) otherwise than by equity shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
Total (a+b+c+d)	10,72,492	4.8387	4.8387
Details of acquisition			
a) Shares carrying voting rights acquired	96,631	0.4360	0.4360
b) VRs acquired otherwise than by equity shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	-	-	-
d) Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others)	-	-	-

Total (a+b+c+d)	96,631	0.4360	0.4360
After the acquisition, holding of acquirer along with PACs of:	11,69,123	5.2746	5.2746
a) Shares carrying voting rights acquired	-	-	-
b) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking / others) Shares pledged with the acquirer	-	-	-
c) VRs otherwise than by equity shares	-	-	-
d) Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	-	-	-
Total (a+b+c+d)	11,69,123	5.2746	5.2746
6. Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)	Open Market		
7. Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	NA		
8. Date of acquisition off/ date of receipt of intimation of allotment of shares /VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	Transactions entered into during the period: From July 22, 2021 to April 28, 2023.		
9. Equity share capital / total voting capital of the TC before the said acquisition	Rs. 22,16,50,620/- (2,21,65,062 shares at the face value of Rs.10 per share)		
10. Equity share capital/ total voting capital of the TC after the said acquisition	Rs. 22,16,50,620/- (2,21,65,062 shares at the face value of Rs.10 per share)		
11. Total diluted share/voting capital of the TC after the said acquisition	Rs. 22,16,50,620/- (2,21,65,062 shares at the face value of Rs.10 per share)		

Part – B

Name of the Target Company: TATVA CHINTAN PHARMA CHEM LIMITED

Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Whether the acquirer belongs to Promoter/ Promoter group	PAN of the acquirer and/ or PACs
Nippon India Mutual Fund	No	

Signature of Authorized Signatory

N. Behar

Authorised Signatory

Place: Mumbai
Date: May 3, 2023

